Business
Hemostemix's Social Media for Investors and Florida's No-Option Patients
Calgary, Alberta--(Newsfile Corp. - August 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTX...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix's Social Media for Investors and Florida's No-Option PatientsCalgary, Alberta--(Newsfile Corp. - August 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to its investor awareness and social media strategies and programs.The investor outreach campaign includes:Opt-in SMS alerts to keep existing and prospective investors updated on corporate milestones - text 905-580-4170 to opt-in.Targeted opt-in email provides company news, clinical developments, and financing updates: email: [email protected],Investor platforms and exchanges (https://www.otcmarkets.com/stock/HMTXF/overview) are designed to increase Hemostemix's visibility, providing due diligence level information that retail and institutional audiences seek about our Company's investment opportunities.\"Hemostemix has sold forward $1,143,983 in Therapy Convertible Debenture year-to-date,\" said Thomas Smeenk, CEO. \"Frost and Sullivan awarded our Company the Biotechnology Company of the Year Award, Asia, in 2007, for VesCell™ achievements. Now, with 498 treatments, 11 peer reviewed publications including 7 clinical studies of 318 subjects, including Phase II results that validate our patients' testimonials, we are ramping up sales in Florida, investor outreach, and patient engagement simultaneously. VesCell™ won the World Economic Forum Technology Pioneer Award because it regenerates new circulation in the body where that need is signaled. Next week, I'm down to Florida to meet with cardiologists who have done their homework - stay tuned\" Smeenk said.Campaign Strategy & Key Highlights - Testimonials and Publications Storytelling: Real patient testimonials about improved cardiac function, reduction of pain and ulcer healing make the science and treatment relatable and compelling.TIME Magazine highlighted VesCell™ recipient, Bob Grinstead, in Take Heart.Watch six time Grammy award winner and VesCell™ recipient Howie Lindeman.Watch Beefsto's Founder, VesCell™ patient #57, Neim M...